FI963630A0 - IFN-beta:n uusia muteiineja - Google Patents

IFN-beta:n uusia muteiineja

Info

Publication number
FI963630A0
FI963630A0 FI963630A FI963630A FI963630A0 FI 963630 A0 FI963630 A0 FI 963630A0 FI 963630 A FI963630 A FI 963630A FI 963630 A FI963630 A FI 963630A FI 963630 A0 FI963630 A0 FI 963630A0
Authority
FI
Finland
Prior art keywords
ifn
beta
muteins
those
recombinant dna
Prior art date
Application number
FI963630A
Other languages
English (en)
Swedish (sv)
Other versions
FI963630A (fi
FI120356B (fi
Inventor
Susan E Goelz
Richard L Cate
E Pingchang Chow
R Blake Pepinsky
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of FI963630A0 publication Critical patent/FI963630A0/fi
Publication of FI963630A publication Critical patent/FI963630A/fi
Application granted granted Critical
Publication of FI120356B publication Critical patent/FI120356B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Amplifiers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
FI963630A 1994-03-15 1996-09-13 IFN-beta:n uusia muteiineja FI120356B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21344894 1994-03-15
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β
PCT/US1995/003206 WO1995025170A1 (en) 1994-03-15 1995-03-13 NOVEL MUTEINS OF IFN-$g(b)
US9503206 1995-03-13

Publications (3)

Publication Number Publication Date
FI963630A0 true FI963630A0 (fi) 1996-09-13
FI963630A FI963630A (fi) 1996-09-13
FI120356B FI120356B (fi) 2009-09-30

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963630A FI120356B (fi) 1994-03-15 1996-09-13 IFN-beta:n uusia muteiineja

Country Status (12)

Country Link
US (2) US5545723A (fi)
EP (1) EP0750668B1 (fi)
JP (2) JP3822903B2 (fi)
AT (1) ATE414152T1 (fi)
AU (1) AU695208B2 (fi)
CA (1) CA2185352C (fi)
DE (1) DE69535883D1 (fi)
DK (1) DK0750668T3 (fi)
FI (1) FI120356B (fi)
NO (1) NO318989B1 (fi)
NZ (2) NZ283217A (fi)
WO (1) WO1995025170A1 (fi)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028007A1 (en) * 1996-12-24 1998-07-02 Biogen, Inc. Stable liquid interferon formulations
EP2599503B1 (en) * 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
IL142350A0 (en) * 1998-10-16 2002-03-10 Biogen Inc Interferon-beta fusion proteins and pharmaceutical compositions containing the same
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003025541A2 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
CN102180944A (zh) 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
ZA200700168B (en) 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
CA2500626A1 (en) * 2002-10-01 2004-04-15 Xencor, Inc. Interferon variants with improved properties
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060281703A1 (en) * 2005-05-19 2006-12-14 Schering Aktiengesellschaft Treatment of disease using an improved regulated expression system
PE20061416A1 (es) * 2005-05-19 2007-01-26 Schering Ag Sistema de expresion genetica que comprende un interferon-beta
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
RS57549B1 (sr) * 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
US20100196328A1 (en) * 2007-04-25 2010-08-05 Tonya Bliss ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION
AU2008247815B2 (en) * 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2207890A4 (en) * 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
WO2010075500A1 (en) 2008-12-23 2010-07-01 Stemcells California, Inc Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim ANALOGUE PEPTIDE OF INTERFERON-BETA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88175C (fi) * 1980-04-03 1993-04-13 Biogen Inc Rekombinant-dna-molekyler och foerfaranden foer framstaellning av polypeptider liknande humant -interferon
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
EP0260350B1 (en) * 1986-09-05 1992-02-12 Cetus Oncology Corporation Oxidation-resistant interferon-beta muteins and their production; formulations containing such muteins
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders

Also Published As

Publication number Publication date
DE69535883D1 (de) 2008-12-24
NO963837D0 (no) 1996-09-13
NZ283217A (en) 1998-05-27
US5545723A (en) 1996-08-13
US6127332A (en) 2000-10-03
CA2185352C (en) 2005-02-22
MX9604073A (es) 1997-12-31
NO318989B1 (no) 2005-05-30
NZ329970A (en) 2000-01-28
AU695208B2 (en) 1998-08-06
JP2006199711A (ja) 2006-08-03
CA2185352A1 (en) 1995-09-21
EP0750668B1 (en) 2008-11-12
ATE414152T1 (de) 2008-11-15
JPH10500563A (ja) 1998-01-20
FI963630A (fi) 1996-09-13
WO1995025170A1 (en) 1995-09-21
JP3822903B2 (ja) 2006-09-20
NO963837L (no) 1996-11-14
AU2120295A (en) 1995-10-03
EP0750668A1 (en) 1997-01-02
DK0750668T3 (da) 2009-03-02
FI120356B (fi) 2009-09-30

Similar Documents

Publication Publication Date Title
FI963630A0 (fi) IFN-beta:n uusia muteiineja
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
EP0787802A3 (fi)
SE9004010D0 (sv) Viralt medel
RU95115239A (ru) Аналог эритропоэтина
WO1995025170B1 (en) NOVEL MUTEINS OF IFN-$g(b)
NO931141L (no) Tnf-muteiner
ATE380866T1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors,deren herstellung und verwendungen
ATE131493T1 (de) Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
DE3788899D1 (de) Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons.
Goelz et al. Muteins of IFN-beta
CA2004202A1 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
IT1262545B (it) Sistema di espressione per linee cellulari eucariotiche

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

FG Patent granted

Ref document number: 120356

Country of ref document: FI

MA Patent expired